We have undertaken a retrospective sequential-cohort analysis of 131 lymphoma patients treated with the BEAM regimen and autologous stem cell transplantation, to compare BEAM at standard doses (sBEAM; n ¼ 67 from May 1990 to April 1995) and BEAM with escalated etoposide dose from 800 to 1600 mg/m 2 (eBEAM; n ¼ 64 from May 1995 to June 1999). Transplant-related mortality and incidence of secondary malignancies were similar in both groups. Disease progression was significantly lower in indolent lymphoma (IL) patients receiving eBEAM (7 vs 43%), although survival was comparable due to a higher toxic mortality in the eBEAM group. The 5-year event-free survival and overall survival were better in Hodgkin's disease (HD) patients treated with eBEAM (70 and 77%, respectively) compared to sBEAM (58 and 69%, respectively), but the difference was not statistically significant. In aggressive lymphomas, no difference was detected between groups. Our results indicate that while escalation of the etoposide doses in the BEAM conditioning regimen does not appear to improve outcome, encouraging results in IL and HD may warrant further studies.
side; lymphoma High-dose chemotherapy supported by autologous stemcell transplantation (ASCT) is widely used for relapsing or resistant non-Hodgkin's lymphoma (NHL) or Hodgkin's disease (HD) patients, and may be a promising procedure for initial therapy of aggressive NHL with poor prognostic features. 1 Under 35% of HD and under 20% of aggressive NHL patients achieve long-term disease-free survival (DFS) with conventional chemotherapy. [2] [3] [4] ASCT results in DFS of 30-65% in primary refractory or relapsed HD [5] [6] [7] [8] [9] [10] and 30-50% in aggressive NHL. [11] [12] [13] [14] [15] [16] Randomized studies have demonstrated the superiority of ASCT to standard salvage chemotherapy for patients with resistant or relapsed HD, 2,3 relapsed aggressive lymphoma 4 or relapsed follicular lymphoma. 17 These results suggest a correlation between dose intensity and disease control. Thus, it is possible that further doseintensification of the conditioning regimen may improve outcome of patients undergoing ASCT. Escalation of the BCNU dose in BEAM and CBV regimens has resulted in increased mortality due to interstitial pneumonitis. 18, 19 Escalation of the melphalan dose resulted in increased mucositis and haemorrhagic cystitis. 20 Mills et al 21 escalated the dose of etoposide in the BEAM protocol from 800 to 1600 mg/m 2 over 4 days, and then to 2400 mg/m 2 over 4 days. The maximum tolerable dose was 1600 mg/m 2 over 4 days, but no conclusions could be drawn regarding the impact of the escalated etoposide dose on tumour response and DFS. We have confirmed 22 that increasing the etoposide dose from 800 to 1600 mg/m 2 in BEAM regimen is not associated with greater early toxicity.
We have now analysed the impact of the etoposide dose in 131 lymphoma patients in terms of early and late toxicities, response and survival.
Patients and methods

Patients
A total of 131 consecutive lymphoma patients treated at a single institution with the BEAM regimen followed by ASCT between May 1990 and June 1999 were included. According to previous classifications based on clinical and histological criteria, 23, 24 patients were classified into three groups: (1) indolent lymphomas (IL), 28 patients (two small lymphocytic, one lymphoplasmacytic, 21 follicular grade 1-2, and four marginal-zone B cell); (2) aggressive lymphomas, 50 patients (four follicular grade 3, 36 diffuse large B cell, six peripheral T-cell unspecified, one angioimmunoblastic and three anaplastic large cell); and (3) HD, 53 patients (30 nodular sclerosis, 17 mixed cellularity and six others). Mantle cell, lymphoblastic and Burkitt's lymphoma cases were excluded. Patients were eligible for ASCT if they were o70 years and had a relapsed lymphoma, or if they had failed to achieve complete remission (CR) after the standard induction chemotherapy. Aggressive NHL patients underwent ASCT in first CR after first-line conventional chemotherapy if they displayed two or more adverse prognostic factors at diagnosis (stages III or IV, performance status X2, extranodal disease, bulky disease, high LDH/b 2 microglobulin levels). Written informed consent using institutionally approved forms was obtained from all patients.
From /kg (0. 16-27.26) , respectively, in the PBPC group. G-CSF (5 mg/kg/day) was administered to 105 patients after transplant, from day þ 6 to haematological recovery (neutrophil count 41 Â 10 9 /l for 3 consecutive days). All patients received antibiotic prophylaxis with a fluoroquinolone (ofloxacin or ciprofloxacin) until neutrophil recovery and trimethoprimsulphamethoxazol during 6 months after transplant.
Toxicity
Haematological toxicity was considered from the day of progenitor cell reinfusion (day 0). Neutrophil recovery was defined as the first of three consecutive days with an absolute neutrophil count (ANC) greater than 0.5 Â 10 9 /l. Platelet recovery was defined as the first of three consecutive days with an unsupported platelet count greater than 20 Â 10 9 /l. Nonhaematological toxicities were evaluated according to the World Health Organization (WHO) grading. Only grade 3 or more toxicities were considered. Transplant-related mortality (TRM) was considered at any time if it was due to a recognized complication of the procedure. Early TRM was defined as death from any cause other than lymphoma occurring within 100 days after high-dose therapy.
Study definitions and assessment of outcome
Patients were evaluated before transplantation with physical examination, computed tomography of the chest, abdomen and pelvis, bone marrow biopsy (if it was previously affected), and other clinical tests as indicated for assessment of the disease (such as gallium-67 scan in HD patients with residual radiographic abnormalities). Patients were defined as having resistant disease if they had received salvage therapy (due to primary refractory disease or relapse), and failed to achieve a partial remission (PR) or CR. Sensitive disease was defined as the reduction X50% in the size of the tumour with the use of conventional salvage chemo or radiotherapy.
Response to BEAM was evaluated 90 days after transplant. CR was defined as the resolution of the abnormalities in tests or physical examination that could be attributed to the lymphoma. PR was defined as more than 50% reduction in the bidimensional measurements of any known site of lymphoma. Progressive disease (PD) was defined as an increase in measurable disease or the appearance of any new lesion. Stable disease (SD) was defined as unmodified disease after the transplant. Overall survival (OS) was calculated from the day of progenitor cell reinfusion (day 0) to the date of death or last follow-up. Event-free survival (EFS) was measured from day 0 until death from any cause, relapse, progression or occurrence of a second neoplasm.
Statistical analysis w
2 test statistics and nonparametric Mann-Whitney tests were used to compare qualitative and quantitative parameters, respectively, between the two BEAM groups (standard and escalated). Differences in haematological recovery and survival between BEAM groups were analysed by Kaplan-Meier and log-rank tests. Comparison of response rates between groups was performed by using the w 2 test. Comparison of TRM rates was performed by using both log-rank test and w 2 test. The impact on survival of the most relevant disease characteristics at diagnosis and at the time of transplant were also analysed by univariate and multivariate analyses. These variables are specified in Table 1 . Differences in survival and haematological recovery between groups according to the different covariates were analysed by log-rank test. A forward stepwise Cox proportional hazard regression model was used for multivariate analysis, including all variables with a P-value o0.1 in univariate analysis. Survival analyses were performed separately in indolent NHL, aggressive NHL and HD. Haematological recovery and toxicity were analysed in the global series, including the variable diagnosis (indolent NHL vs aggressive NHL vs HD).
All P-values reported are two-sided and statistical significance is defined as a P-value less than 0.05. The statistical analyses were computed with SPSS statistical software (SPSS, Inc., Chicago, IL, USA). Table 1 shows patient characteristics. There were significant differences between groups. There were no
Results
Patient characteristics
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A Martín et al differences in antibiotic prophylaxis between the two BEAM groups.
Haematological recovery
Comparison stratified for stem cell source showed no significant difference between standard BEAM and eBEAM with respect to neutrophil (P ¼ 0.46) and platelet recovery (P ¼ 0.52).
Early and late toxicities
As shown in Table 2 , grade 3-4 mucositis was more frequent with eBEAM. Other toxicities were comparable.
Seven patients (5.3%) experienced early procedure-related mortality, two patients (3.0%; 95% confidence interval (CI): 0.4-10.4%) in the standard BEAM group (bacterial infection, interstitial pneumonitis/ARDS), and five (7.8%; 95% CI: 2.6-17.3%) in the eBEAM group (P ¼ 0.43) (bacterial infection, fungal infection, interstitial pneumonitis/ARDS, multiorgan failure, graft failure). Another eight patients died after the first 100 days from transplant-related causes; four in each group. Overall, TRM was 12% at 5 years; 9% (95% CI: 1-16%) and 15% (95% CI: 6-24%) in the sBEAM and eBEAM groups, respectively (log-rank P ¼ 0.20). Five patients (4%) developed a secondary malignancy at a median time of 27.3 months (range, 11-83.6) after transplantation; three after sBEAM (4.5%; 95% Escalated BEAM in autologous transplantation A Martín et al CI: 0.9-12.5%; two MDS and one T-lymphoproliferative disease), and two after eBEAM (3.1%; 95% CI: 0.4-10.8%; one MDS and one melanoma). The 5-year cumulative probability of secondary malignancy was 4% in each group.
Previous treatment
No. of chemotherapy lines 1 2 9 2 1 4 1 4 8 4 1 8 2 3 6 4 3 4 1 3 5 5 8 5 2 X3 3 6 3 6 1 8 1 7 3 8 3 0 Previous radiotherapy 7 14 4 13 38
Response to transplant
Responses were comparable (Table 3) .
Survival analysis
The median follow-up of surviving patients is 98 months (range: 64-140 months) in the standard BEAM group, and 52 months (range: 16-80 months) in the eBEAM group. Indolent NHL. At the time of this analysis, progression of lymphoma has been documented in six (43%) patients in the standard BEAM group and in only one patient (7%) in the eBEAM group (P ¼ 0.029). Nine patients have died, three (21%) patients on the standard BEAM group (from disease progression), and six (43%) patients on the eBEAM group (disease progression, one; early TRM, two; late TRM, three). Figure 1 illustrates the Kaplan-Meier survival curves. The 5-year estimated EFS and OS were not significantly different between the standard BEAM (57% (95% CI: 31-83%) and 78% (95% CI: 57-100%), respectively) and eBEAM groups (56% (95% CI: 30-83%) and 55% (95% CI: 29-82%), respectively).
Aggressive NHL. Progression of lymphoma has been documented in nine patients in each group. A total of 18 patients have died, 11 (41%) patients on the standard BEAM group (disease progression, nine; early TRM, one; late TRM, one), and seven (30%) patients on the eBEAM Table 3 Response to transplant Time from ASCT (years) Figure 2 , the 5-year estimated EFS and OS were not significantly different between standard BEAM (59% (95% CI: 41-78%) and 63% (95% CI: 45-81%), respectively) and eBEAM (56% (95% CI: 36-77%) and 69% (95% CI: 50-88%), respectively).
Indolent lymphomas P
HD. Progression of lymphoma has been documented in nine (34%) and five (18%) patients in the standard and escalated BEAM groups, respectively (P ¼ 0.18). A total of 16 patients have died, 10 (38%) patients in the standard BEAM group (disease progression, six; early TRM, one; late TRM, three), and six (22%) patients in the escalated BEAM group (disease progression, one; toxicity of second transplant, one; early TRM, three; late TRM, one). As shown in Figure 3 , the 5-year estimated EFS and OS was slightly better in the eBEAM group (70% (95% CI: 53-87%) and 77% (95% CI: 62-93%), respectively) as compared with standard BEAM group (58% (95% CI: 39-77%) and 69% (95% CI: 51-87%), respectively), but the difference did not reach statistical significance.
Multivariate analysis. The results of the multivariate analysis of variables affecting survival are shown in Table 4 . In indolent NHL patients, age at transplant was the only significant independent prognostic factor for OS, whereas the number of previous chemotherapy lines was the only independent prognostic factor for EFS (Table 4) . After adjustment for age and number of chemotherapy lines and using the stratified Kaplan-Meier analyses, conditioning regimen (standard BEAM vs eBEAM) was not significantly associated with OS (P ¼ 0.58) nor EFS (P ¼ 0.42). In aggressive NHL and HD patients, disease status at transplant was the most important prognostic factor for both EFS and OS (Table 4) . After adjustment for status at transplant and using the stratified Kaplan-Meier analyses, conditioning regimen (standard BEAM vs 
Discussion
We did not find any significant difference in terms of response rates to transplant, OS or EFS between patients who received BEAM at standard doses and those who received the escalated dose of etoposide. The shortcomings of this study are a heterogeneous patient population, small number of patients in each disease category, and some imbalances in patient characteristics and type of stem cell source between sBEAM and eBEAM.
In accordance with previous work, 5, 6, 9, 10, 12, 15, 16 disease status at transplant was the most important prognostic factor influencing outcome in aggressive NHL and HD patients (indolent lymphoma cases were transplanted in CR or with sensitive disease). Comparison stratified for status at transplant did not show significant differences in survival between sBEAM and eBEAM. In patients with indolent lymphoma, age at transplant was the most important factor influencing OS (with a threshold around 50 years), as previously reported in other series. 25, 26 In our study, the ages of patients receiving sBEAM or eBEAM were significantly different (median 40 for sBEAM and 52 for eBEAM). However, a comparison stratified for age did not show significant survival differences between sBEAM and eBEAM.
eBEAM transplants were performed more recently than the sBEAM transplants. Transplant results have improved over time, probably due to improvements in supportive care and refinements in patient selection. 10, 16, 27 Thus, the lack of difference further supports the conclusion that eBEAM does not seem to improve results. We did find better EFS and OS with eBEAM over sBEAM in HD patients, although the difference did not reach statistical significance. Interestingly, in patients with indolent lymphoma, disease progression after transplant was significantly lower in the eBEAM group as compared to the standard BEAM group (7 vs 43% of patients, respectively). This is an interesting finding because most indolent lymphoma patients still relapse after ASCT. 25, 26 However, the lower relapse rate was not associated with improved survival due to a higher toxic mortality in the eBEAM group (5/14) as compared to the standard BEAM group (0/14).
The eBEAM regimen was reasonably well tolerated. Only grade 3-4 mucositis was more frequent among patients in the eBEAM group as compared to the standard BEAM group. Incidence of early TRM was similar in the two groups, and comparable to other recent Table 4 Prognostic factors influencing survival in multivariate analysis studies. 10, 15, 16, 28 The incidence of late TRM was also similar between the two BEAM groups, with the incidence of secondary malignancies being comparable to that reported in the literature. 10, 15, 29, 30 Other groups have attempted to intensify the conditioning regimen in order to improve the results of the transplant. The majority of reported studies have explored the addition of etoposide to the standard regimen of totalbody irradiation (TBI) and cyclophosphamide. [31] [32] [33] [34] [35] The pilot trials of Gulati et al, 31 Horning et al, 33 and Weaver et al 34 appear to show a reduction in relapses when compared retrospectively with historical controls. However, these studies were hampered by heterogeneity of the study population and short follow-up. In addition, toxic death rate was unacceptably high in some of them, such as 30% reported by Gulati et al. 31 More recently, Stiff et al 35 have reported the results of a prospective phase II trial with a cyclophosphamide/etoposide/TBI and an augmented BCV preparative regimens for patients with relapsed or refractory diffuse aggressive NHL. The overall toxic death rate was 10.3%, and the results for those patients with chemoresistant disease are among the best reported to date, suggesting a benefit of the more aggressive regimens for this subset of patients. Obviously, a true assessment of the usefulness of augmented conditioning regimens should only come from a prospective randomized clinical trial.
In conclusion, our long-term follow-up results show that early and late toxicities associated with eBEAM regimen are acceptable. However, the data derived from this study do not indicate that the escalated etoposide doses in the BEAM conditioning regimen improves the results of conventional BEAM for ASCT in lymphoma patients, although the benefits obtained in indolent lymphoma and HD patients are encouraging and may deserve further studies.
